866-997-4948(US-Canada Toll Free)

Diabetic Peripheral Neuropathy - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Feb 2017

Category :

Pharmaceutical

No. of Pages : 47 Pages

Diabetic Peripheral Neuropathy - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Peripheral Neuropathy Pipeline Review, H1 2017, provides an overview of the Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline landscape.

Diabetic neuropathy is nerve damage caused by diabetes. The type of neuropathy occurring in the arms, hands, legs and feet is known as diabetic peripheral neuropathy. Symptoms include numbness or tingling in the feet pain or discomfort in the feet or legs-including prickly, sharp pain or burning feet, muscle weakness and loss of muscle tone in the feet and lower legs, loss of balance, dry feet and cracked skin. The predisposing factors include diabetes, smoking and kidney diseases. Treatment includes antidepressants, anti-seizure and opioid analgesics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Peripheral Neuropathy Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Diabetic Peripheral Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Peripheral Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 2, 1 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Peripheral Neuropathy (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Peripheral Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Peripheral Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Peripheral Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Peripheral Neuropathy (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Peripheral Neuropathy (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Diabetic Peripheral Neuropathy - Overview 6
Diabetic Peripheral Neuropathy - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 9
Products under Development by Companies 10
Products under Development by Universities/Institutes 11
Diabetic Peripheral Neuropathy - Therapeutics Assessment 12
Assessment by Target 12
Assessment by Mechanism of Action 14
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Diabetic Peripheral Neuropathy - Companies Involved in Therapeutics Development 20
Achelios Therapeutics Inc 20
Celgene Corp 20
Commence Bio Inc 21
KPI Therapeutics Inc 21
Medifron DBT Co Ltd 22
Relief Therapeutics Holding AG 22
ViroMed Co Ltd 23
Diabetic Peripheral Neuropathy - Drug Profiles 24
atexakin alfa - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
BNV-222 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
CMB-200 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
ketoprofen - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
MDR-652 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
ND-07 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
PDA-002 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
pirenzepine hydrochloride - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Small Molecules for Pain - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Small Molecules to Inhibit Hsp90 for Peripheral Neuropathy and Neurodegenerative Disorders - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
U-2902 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
VM-202 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Diabetic Peripheral Neuropathy - Dormant Projects 41
Diabetic Peripheral Neuropathy - Discontinued Products 42
Diabetic Peripheral Neuropathy - Product Development Milestones 43
Featured News & Press Releases 43
Sep 08, 2016: ViroMed proceeding with the Worlds first phase III gene therapy clinical trial for diabetic peripheral neuropathy 43
Jun 27, 2016: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate, VM202, in Painful Diabetic Peripheral Neuropathy 43
Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition 44
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 46
Disclaimer 47

List of Tables
Number of Products under Development for Diabetic Peripheral Neuropathy, H1 2017 7
Number of Products under Development by Companies, H1 2017 8
Number of Products under Development by Universities/Institutes, H1 2017 9
Products under Development by Companies, H1 2017 10
Products under Development by Universities/Institutes, H1 2017 11
Number of Products by Stage and Target, H1 2017 13
Number of Products by Stage and Mechanism of Action, H1 2017 15
Number of Products by Stage and Route of Administration, H1 2017 17
Number of Products by Stage and Molecule Type, H1 2017 19
Diabetic Peripheral Neuropathy - Pipeline by Achelios Therapeutics Inc, H1 2017 20
Diabetic Peripheral Neuropathy - Pipeline by Celgene Corp, H1 2017 20
Diabetic Peripheral Neuropathy - Pipeline by Commence Bio Inc, H1 2017 21
Diabetic Peripheral Neuropathy - Pipeline by KPI Therapeutics Inc, H1 2017 21
Diabetic Peripheral Neuropathy - Pipeline by Medifron DBT Co Ltd, H1 2017 22
Diabetic Peripheral Neuropathy - Pipeline by Relief Therapeutics Holding AG, H1 2017 22
Diabetic Peripheral Neuropathy - Pipeline by ViroMed Co Ltd, H1 2017 23
Diabetic Peripheral Neuropathy - Dormant Projects, H1 2017 41
Diabetic Peripheral Neuropathy - Discontinued Products, H1 2017 42

List of Figures
Number of Products under Development for Diabetic Peripheral Neuropathy, H1 2017 7
Number of Products under Development by Companies, H1 2017 8
Number of Products by Top 10 Targets, H1 2017 12
Number of Products by Stage and Top 10 Targets, H1 2017 12
Number of Products by Top 10 Mechanism of Actions, H1 2017 14
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017 14
Number of Products by Routes of Administration, H1 2017 16
Number of Products by Stage and Routes of Administration, H1 2017 16
Number of Products by Molecule Types, H1 2017 18
Number of Products by Stage and Molecule Types, H1 2017 18

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *